Welcome to our dedicated page for PERKINELMER news (Ticker: PKI), a resource for investors and traders seeking the latest updates and insights on PERKINELMER stock.
This PKI news page is best understood in the context of the information provided for Revvity, Inc. (NYSE: RVTY), which appears in the supplied news releases. While PKI historically referred to PerkinElmer in analytical laboratory instrument manufacturing, the current news flow in the input is associated with Revvity, a health science company whose activities span discovery to development, and diagnosis to cure.
The news items describe Revvity as providing health science solutions, technologies, expertise, and services, with focus areas that include translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, and informatics. They also note that Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia, and governments, and that it is part of the S&P 500 index with customers in more than 160 countries.
Across the sample releases, typical news topics include quarterly financial results, dividend declarations, product launches in diagnostics and life sciences, and participation in healthcare investor conferences. Examples in the input include announcements of new reagent technologies for drug discovery, reference standards for oncology diagnostic testing workflows, and automated analytical platforms for specialty testing, as well as updates on earnings calls and financial performance.
For users researching PKI, this page therefore functions as an entry point into the more recent narrative presented under Revvity’s RVTY symbol in the provided material. Readers can use the news feed to follow themes such as health science product introductions, diagnostics and life sciences workflow tools, and financial reporting, as reflected in the supplied press releases.
PerkinElmer has signed an agreement to divest its Applied, Food, and Enterprise Services businesses to New Mountain Capital for $2.45 billion. Of this, $2.30 billion will be received at closing, with $150 million contingent on future valuations. Post-transaction, PerkinElmer will focus solely on Life Sciences and Diagnostics, projected to generate $3.3 billion in 2022 revenue, with over 10% annual organic growth. The divestiture is expected to close in Q1 2023.
The Board of Directors of PerkinElmer, Inc. (NYSE: PKI) has declared a regular quarterly dividend of $0.07 per share. This dividend is set to be paid on November 11, 2022, to shareholders of record as of the close of business on October 21, 2022. In 2021, the company reported revenue of approximately $5 billion and employs over 16,000 people globally. PerkinElmer is committed to innovation for a healthier world and is a component of the S&P 500 Index.
PerkinElmer, Inc. (NYSE:PKI) has appointed Dr. Michelle McMurry-Heath to its board of directors, effective July 22, 2022. Dr. McMurry-Heath brings extensive experience in research and science policy, having served as President and CEO of the Biotechnology Innovation Organization. Her strong advocacy for equitable access to medical innovations and leadership roles at Johnson & Johnson and the FDA position her well to contribute to PerkinElmer's growth strategy post-portfolio transformation. The company reported revenues of approximately $5 billion in 2021 and continues to prioritize innovation in healthcare.
PerkinElmer, Inc. (NYSE: PKI) will release its Q2 2022 financial results on August 4, 2022, at 6:00 a.m. ET. A conference call will follow at 8:00 a.m. ET, hosted by CEO Prahlad Singh and CFO Jamey Mock. The call will be accessible via a registration form on their website. A replay will be available from 10:00 a.m. ET the same day. The company reported $5 billion in revenue for 2021 and serves customers in 190 countries.
PerkinElmer (NYSE: PKI) launched the GC 2400™ Platform, an innovative automated gas chromatography solution aimed at enhancing lab productivity and precision. Designed for pharmaceutical, food, environmental, and industrial applications, it combines systems, software, and consumables to streamline operations. Key features include automated sampling, reduced hands-on time, and a wireless touchscreen interface. Built-in sensors promote sustainability by minimizing gas consumption. The platform will be showcased at Analytica Germany and Analytica Latin America.
PerkinElmer (NYSE: PKI) has launched the BioQule™ NGS System, an innovative benchtop solution for next-generation sequencing (NGS) library preparation. This system allows labs to automate the process for up to eight samples, featuring integrated quality control and liquid handling technology. Unlike existing solutions, the BioQule provides in-built quantification of created libraries and requires only 10 ng of starting material. It is suitable for various lab sizes and does not necessitate prior automation experience. The system will be showcased at the AGBT General Meeting in Orlando from June 6-9, 2022.
PerkinElmer reports Q1 2022 revenue of $1.26 billion, down from $1.31 billion a year prior. GAAP EPS from continuing operations is $1.40 compared to $3.37 in Q1 2021. The company initiates guidance for Q2 2022, forecasting revenue of $1.20-1.22 billion and expects adjusted EPS between $2.00-2.05. For the full year, expected revenue is $4.56-4.63 billion with adjusted EPS of $7.15-7.45. Despite revenue declines, the company highlights significant growth in the Discovery & Analytical Solutions segment with a 33% increase.
PerkinElmer, Inc. (NYSE: PKI) has declared a quarterly dividend of $0.07 per share, to be paid on August 12, 2022. This dividend is for shareholders on record as of July 22, 2022. In 2021, the company reported approximately $5 billion in revenue and employs over 16,000 individuals, serving customers across 190 countries. PerkinElmer is part of the S&P 500 Index, indicating its significant presence in the market.
PerkinElmer, Inc. (NYSE: PKI) will announce its first quarter 2022 financial results after market close on May 3, 2022. The company will host a conference call that same day at 5:00 p.m. ET to discuss the results, led by CEO Prahlad Singh and CFO Jamey Mock. Investors can access the call through a live audio webcast available on the company's website, with a replay starting at 7:00 p.m. ET the same day. PerkinElmer reported approximately $5.0 billion in revenue in 2021 and operates in 190 countries.
PerkinElmer, Inc. (NYSE: PKI) has launched the Vega® imaging system, an innovative automated ultrasound platform aimed at enhancing preclinical research in cancer, liver and kidney diseases, and cardiology. The system allows for hands-free operation and high-throughput scanning, improving research efficiency. Key features include advanced imaging modes for better visualization of diseases and therapies. This technology was acquired through PerkinElmer's purchase of SonoVol, Inc. The company recently reported revenues near $5 billion in 2021, supporting its position in the S&P 500.